Hawaii 2023 Regular Session

Hawaii House Bill HR206

Introduced
3/10/23  

Caption

Requesting The Department Of Health To Convene A Therapeutic Psilocybin Working Group.

Impact

If HR206 is enacted, it would empower the Department of Health to compile a comprehensive overview of the federal, state, and county legislation regarding psilocybin's medical use. The Working Group will specifically assess scientific studies and existing jurisdictions where psilocybin has been legalized for therapeutic purposes. Thus, the resolution endeavors to address significant mental health issues by creating a framework for potential legislative changes regarding the use of psilocybin in Hawaii.

Summary

House Resolution 206 (HR206) requests the Department of Health in Hawaii to convene a Therapeutic Psilocybin Working Group aimed at exploring the benefits and regulations surrounding the therapeutic use of psilocybin for mental health treatment. This arises from a growing recognition of mental health challenges within the state, exacerbated by a shortage of mental health professionals. The resolution emphasizes the importance of considering innovative treatment options like psilocybin that have shown promise in addressing conditions such as PTSD, anxiety, and other forms of psychological distress.

Contention

While the bill seeks to address urgent mental health needs, there may be contentions surrounding the implications of legalizing psilocybin-based treatments. Advocates for mental health reform support the measure, citing examples from states like Colorado and Oregon where psilocybin has been beneficial. However, opponents may raise concerns about the societal impacts, the safety of such treatments, and the potential for misuse. The bill indicates a shift towards more open discussions on alternative therapies, yet it will likely face scrutiny as the Working Group develops its recommendations.

Companion Bills

HI HCR202

Same As Requesting The Department Of Health To Convene A Therapeutic Psilocybin Working Group.

Previously Filed As

HI HB1337

Relating To Psilocybin.

HI SB1454

Relating To Psilocybin.

HI HR33

Requesting The Department Of Human Services To Convene A Baby Bonds Working Group.

HI HCR44

Requesting The Department Of Human Services To Convene A Baby Bonds Working Group.

HI SCR39

Requesting The Department Of Human Services To Convene A Baby Bonds Working Group.

HI SR28

Requesting The Department Of Human Services To Convene A Baby Bonds Working Group.

HI SCR132

Requesting The Office Of The Governor To Convene A Working Group To Plan For The Remediation Of Perfluoroalkyl And Polyfluoroalkyl Substances (pfas) In The State.

HI SR114

Requesting The Office Of The Governor To Convene A Working Group To Plan For The Remediation Of Perfluoroalkyl And Polyfluoroalkyl Substances (pfas) In The State.

HI HR140

Requesting The Department Of Agriculture To Convene A Working Group To Review The Effectiveness Of The Relevant State Laws Governing Agricultural-based Commercial Operations.

HI HCR161

Requesting The Department Of Agriculture To Convene A Working Group To Review The Effectiveness Of The Relevant State Laws Governing Agricultural-based Commercial Operations.

Similar Bills

HI HCR202

Requesting The Department Of Health To Convene A Therapeutic Psilocybin Working Group.

HI SCR133

Requesting The Department Of Health To Convene A Therapeutic Psilocybin Working Group.

HI SR153

Requesting The Department Of Health To Convene A Therapeutic Psilocybin Working Group.

HI SR88

Requesting The Department Of Health To Convene A Therapeutic Psilocybin Working Group To Examine The Medicinal And Therapeutic Effects Of Psilocybin And Develop A Longterm Strategic Plan, Should Food And Drug Administration Approval For Medical Use Be Obtained, To Enable The Availability Of Therapeutic Psilocybin Or Psilocybin-based Products That Are Safe, Accessible, And Affordable For Adults Twenty-one Years Of Age Or Older.

HI HB2400

Relating To Psilocybin.

HI SB3160

Relating To Psilocybin.

HI SCR100

Requesting The Department Of Health To Convene A Therapeutic Psilocybin Working Group To Examine The Medicinal And Therapeutic Effects Of Psilocybin And Develop A Long-term Strategic Plan, Should Food And Drug Administration Approval For Medical Use Be Obtained, To Enable The Availability Of Therapeutic Psilocybin Or Psilocybin-based Products That Are Safe, Accessible, And Affordable For Adults Twenty-one Years Of Age Or Older.

HI SB1454

Relating To Psilocybin.